GLP-1 receptor agonists are primarily known for aiding weight loss, but emerging research indicates they may also provide significant cardiovascular and renal benefits. This article discusses the mechanisms behind these effects, highlights key clinical trials, and emphasizes the…
A new clinical trial aims to investigate whether a gradual reduction in semaglutide dosage before complete cessation can lead to better weight maintenance and cardiometabolic outc…
A recent study funded by the NIH has uncovered how newer oral GLP-1 drugs, including orforglipron and danuglipron, affect the brain's reward circuits in mice, potentially reducing…
A recent study has found that GLP-1 drugs like Wegovy and Ozempic, used for obesity and type 2 diabetes, may be associated with a higher risk of hair loss, particularly non-scarri…
Recent discussions around glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss highlight their effects on mood and sexual desire. While these medications can suppress…
Research from the University of Hong Kong indicates that GLP-1 medications may help prevent lung scarring in individuals with type 2 diabetes following COVID-19. The study highlig…
A recent study published in the journal Circulation indicates that obesity rates in the United States have risen significantly, with approximately 40% of adults and 20% of childre…